Secondary resistances—which appears after first responses to treatment—remain an important area of cancer research. Over time, secondary resistance may cause originally successful treatments to lose their effectiveness, which can result in tumor regrowth and poor patient outcomes.
The absence of preclinical models that faithfully reproduce the emergence of secondary resistance has slow down the development of treatments designed to overcome or prevent this phenomenon. Antineo paves the way to fill this gap by developing innovative preclinical tumor models that specifically mimic secondary resistance. This provides our clients unique tools to understand the underlying mechanisms of resistance and investigate new treatment strategies.
Antineo has developed over 30 preclinical tumor models resistant to standard immunotherapies or chemotherapies. These models are derived from tumors treated repeatedly with immune checkpoint inhibitors, such as anti-PD1 or anti-PDL1, or other standard of care treatments. These tumors are then passaged from one mouse to another and kept under selection pressure.
We offer a wide range of resistant syngeneic and CDX (cell-derived xenograft) models. These models are particularly suited for:
-
Evaluate the efficacy of second-line therapies :
Our models enable our clients to assess innovative compounds designed specifically to target secondary resistance mechanisms in tumors. This helps identify promising treatments that could restore the efficacy of first-line therapies or overcome this resistance.
-
Investigating resistance reversal strategies:
Thanks to our preclinical models, researchers can examine methods for adapting to acquired resistance, such as combination therapies that target immune evasion pathways or amplify the immune response, offering critical insights into how to overcome resistance in the clinic.
